Table 1.

Summary of publications describing the impact of HU on ACS in patients with sickle cell disease

Summary of publications describing the impact of HU on ACS in patients with sickle cell disease

Follow-up times are given as mean or median as reported by each study. pt-y indicates patient-years; Hgb, hemoglobin, IRR, incidence rate ratio; and HR, hazard ratio.

*Secondary analysis.

†Publication described as a nonrandomized trial, but those on HU were not compared with patients not on HU (ie, no control group comparisons were reported).

Close Modal

or Create an Account

Close Modal
Close Modal